smithkline beecham the anglo-us pharmaceuticals and consumer products group is to create a partnership with marion merrell dow to develop and market over-the-counter otc non-prescription medicines in the us the new group would have had sales last year of dollars 660 m pounds 345.5 m and operating profits of dollars 120 m making it the fifth largest otc group in the us smithkline beecham's shares closed down 7 p at 455 p smithkline beecham will initially own 90 per cent and marion merrell dow 10 per cent of the partnership smithkline beecham's american otc sales last year were about dollars 550 m while marion merrell dow's were dollars 111 m the aim is a 50-50 arrangement as new products are licensed the companies said they were committed to similar co-operation in other countries mr john ziegler north american president of smithkline beecham consumer brands will lead the partnership mr bob bauman the anglo-us group's chief executive said when smithkline beecham was created we said our vision was to achieve leadership in healthcare and in each of our four business segments he added that the partnership with marion merrell dow was another step towards achieving this goal both groups have prescription products that could be marketed by the new group smithkline beecham has asked the us food and drug administration fda for an otc licence for tagamet the anti-ulcer drug whose patents run out in 1994 it had worldwide sales last year of more than dollars 1 bn marion merrell dow said it might seek otc licences for seldane an anti-histamine and the anti-smoking products nicorette and nicoderm nicoderm which uses a transdermal patch was launched in 1991, and had sales of dollars 137 m during the first six months of this year the deal is rather imprecise said mr jonathan de pass pharmaceuticals analyst at bzw it all depends on whether they receive fda approval for seldane and tagamet and whether they successfully extend the relationship worldwide if they do the implications are enormous safety concerns about the new partnership's seldane and tagamet may delay or prevent fda approval seldane is potentially dangerous to patients with a damaged liver or those taking two other drugs ketoconazole an anti-fungal treatment and erythromycin an antibiotic there are also fears that patients with stomach cancer could mis-diagnose an ulcer and buy tagamet